A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis
Latest Information Update: 04 Jul 2025
At a glance
- Drugs LNK 01001 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Lynk Pharmaceuticals
Most Recent Events
- 27 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 19 Mar 2024 Status changed from not yet recruiting to recruiting.
- 29 Feb 2024 New trial record